CYP2E1-IN-1

CYP2E1-IN-1 (Compound 10) is an orally active cytochrome P450 2E1 (CYP2E1) inhibitor with a Kd of 7.02 μM, an IC50 of 1.64 μM, and a Ki of 0.897 μM. CYP2E1-IN-1 activates the Nrf2/HO-1 signaling pathway and inhibits ROS production, thereby alleviating pancreatic injury. CYP2E1-IN-1 has significant anti-inflammatory and antioxidant activities and can effectively reduce inflammation and oxidative stress in severe acute pancreatitis (SAP) . CYP2E1-IN-1 can be used in the study of SAP and other inflammatory-related diseases[1].

38205-55-9

12352005

H302, H315, H319, H335

Cytochrome P450; Heme Oxygenase (HO) ; Keap1-Nrf2; Reactive Oxygen Species (ROS)

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

COVID-19-immunoregulation

Inflammation/Immunology

99.95

DMSO : 200 mg/mL (ultrasonic)

CC(C1=C(N=CS1)C)=O

C6H7NOS

141.19

H302, H315, H319, H335

[1]Qiu J, et al. Discovery of a CYP2E1 inhibitor and its therapeutic potential in severe acute pancreatitis. Eur J Med Chem. 2025 Aug 5;292:117666.

Room Temperature

Store at room temperature 3 years

http://file.medchemexpress.com/batch_PDF/HY-W072025/CYP2E1-IN-1-SDS-MedChemExpress.pdf

Reference compound2

No Development Reported